PMC7154254_01
CT scan showing a cranial bone tumor which has infiltrated the surrounding tissue as an extra bone mass (arrows).
cro-0013-0249-g01.jpg
PMC7154254_01_cro-0013-0249-g01.jpg
F1
IMDC intermediate risk and received sunitinib for an initial 7 months, axitinib for the next 6 months as second-line therapy, and nivolumab for the following 6 months as third-line therapy. In spite of these treatments, CT revealed that the cranial bone tumors had increased in size, infiltrating the surrounding tissue as an extra bone mass (Fig. 1), and a new liver lesion had appeared.
a CT scan showing a lung metastatic lesion (arrow) before the introduction of pazopanib. b CT scan showing a decreased lung metastatic lesion (arrow) on Day 12 after the initiation of pazopanib.
cro-0013-0249-g02.jpg
PMC7154254_01_cro-0013-0249-g02.jpg
F2
Her chest and abdomen CT showed that the lung metastasis had decreased (Fig. 2).